Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0029463 (osteosarcoma)
 16,637 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The cellular immune reactivity of 24 patients with osteogenic sarcoma was studied longitudinally during surgical treatment and subsequent adjuvant chemoimmunotherapy. Cellular immune function was studied using in vitro assays of lymphocyte reactivity to mitogens and nonspecific allogenic antigens. Circulating cells were characterized by the total lymphocyte and wbc counts, determination of E-rosetting populations, and percent of polymorphonuclear leukocytes. Both fresh and cryopreserved lymphocytes were utilized and compared. The preoperative values from these studies offered no useful indication of those patients likely to have disease recurrence. Likewise, longitudinal studies during the course of adjuvant treatment did not predict relapse before other routine clinical studies could identify it. There was no difference in the studied lymphocyte functions and hematologic tests between the group receiving BCG immunotherapy and those not receiving BCG. Our studies indicate that current measures of cellular immune function are of little value in the monitoring of patients with osteogenic sarcoma.
 ...
PMID:Longitudinal studies of cellular immunity of patients with osteogenic sarcoma during chemoimmunotherapy. 693 4

The effects of immunotherapy with irradiated tumour cells and BCG were studied in non-metastasizing variety of the Dunn osteosarcoma transplantable in mice. Experimental animals which had been preimmunized with three injections of 0.7 to 1.4 X 10(6) irradiated tumour cells each 1 to 3 weeks before administration of 1 X 10(6) living tumour cells, showed a tumour incidence of 23 per cent. This was significantly (P less than 0.005) lower than the 92 per cent tumour incidence in the control animals. Non-specific immunotherapy with BCG given subcutaneously at a dose of 1.0 mg of dry-weight bacterial mass three times at 3-week intervals was found to have no protective effect against the osteosarcoma. The tumour incidence was 90 per cent for BCG-treated and 94 per cent for control animals. The osteosarcomas were studied light and electron microscopically and also with regard to the histochemical alkaline phosphatase activity. No structural difference was found between the tumours of the various groups. The demonstrated immunotherapeutic response is in contrast to the low degree of immunogenicity of the osteosarcoma, which we will report elsewhere.
 ...
PMID:Immunotherapy with irradiated tumour cells and BCG in experimental osteosarcoma. 694 51

Canine and human osteogenic sarcomas, like most other malignant tumors, cause or are associated with progressive impairment of host immune reactivity. Adjuvant immunotherapy with live BCG had shown increased survival in one study of canine disease. Experiments with induced fibrosarcomas in mice had suggested that some of the host immune defect might be ameliorated by splenectomy. A prospective clinical trial was conducted with several cooperating veterinary centers. Dogs with osteosarcoma apparently confined to a limb were randomized to be treated by amputation and methanol-extracted residue of BCG (MER), or by the same modalities plus splenectomy. Randomization was discontinued relatively early in the study because of higher mortality in the splenectomy group. Animals treated by amputation and MER could be compared only with historic controls; median and one-year survival rates did not differ significantly from those of prior series. Animals treated by amputation, splenectomy, and MER had significantly poorer survival.
 ...
PMID:Canine osteogenic sarcoma treated by amputation and MER: an adverse effect of splenectomy on survival. 695 Aug 1

Twenty-one patients with osteogenic sarcoma of the limbs were treated with an early combination of 1,750 rad whole lung irradiation, alternate cyclic chemotherapy with high-dose methotrexate, vincristine, mitomycin C, adriamycin, immidazol carboxamide (DTIC), cyclophosphamide, and intercalated immuno-BCG. The primary lesion was treated either by amputation or an 8,000 rad irradiation. Patients have been followed up for 6-29 months. Three patients relapsed, respectively, after 8, 11, and 22 months. All three patients had a long delay in completing the first part of treatment (first cycles A and B and lung irradiation). The 18 other patients are disease-free. Local relapses have not been observed. The toxicity of this protocol appears to be acceptable, but a longer follow-up is necessary to more precisely discern the efficacy and tolerance of the lung to this combined treatment.
 ...
PMID:A strategic adjuvant therapy of osteosarcoma. 703 73


<< Previous 1 2